The most commonly-reported TEAEs in the tafolecimab groups included upper respiratory tract infection, increased blood creatine phosphokinase, increased alanine aminotransferase, increased aspartate aminotransferase and hypertension (Table 3). The gene discussed is GPT; the disease is hypertensive disorder.